Phase II multicenter randomized controlled clinical trial on the efficacy of intra-articular injection of autologous bone marrow mesenchymal stem cells with platelet rich plasma for the treatment of knee osteoarthritis

Table 3 WOMAC scores before administration of treatments and 3, 6 and 12 months afterwards

WOMAC	Time	PRGF	BM-MSCs + PRGF
Pain	Baseline	6.6 (2.9)	6.6 (4.4)
	3 months	4.3 (3.3)**	4.6 (3.3)*
	6 months	4.4 (3)**	4.3 ( 3.6)
	12 months	4.5 (3.2)**	4.1 (3.6)
	Improvement (%)	27.3	45.5
Stiffness	Baseline	3 (1.6)	3.3 (2.1)
	3 months	1.9 (1.4)**	2.3 (2.2)**
	6 months	2.2 (1.6)	2 (1.9)*
	12 months	2.1 (1.6)*	2.1 (1.9)
	Improvement (%)	33.3	50
Physical function	Baseline	22.3 (12.8)	23.5 (13.2)
	3 months	15.5 (12.6)**	17.6 (12.6)*
	6 months	16.3 (11.1)*	14.9 (11.8)*
	12 months	15.5 (11.9)**	16.7 (11.6)*
	Improvement (%)	24.4	28.6
Overall	Baseline	31.9 (16.2)	33.4 (18.7)
	3 months	21.7 (17.1)**	24.4 (17.4)*
	6 months	23 (15)**	21.3 (16.6)*
	12 months	22.3 (15.8)**	23.0 (16.6)^#
	Improvement (%)	23.4	37.3

At baseline, 3 months, 6 months and 12 months, data are presented as mean (SD). Intragroup comparisons between follow-up values and baseline values of WOMAC score: *p < 0.01; **p < 0.05, ^#p = 0.05. Improvement (%) is the median improvement in percentage between the basal value and 12 months

ISSN: 1479-5876